
Walgreens Boots Alliance 'Specialty Pharmacy Accelerator' Says It Helps Lower Out-of-Pocket Costs, Improve Outcomes for People with MS
Multiple sclerosis (MS) treatment involves specialty medications that often incur high out-of-pocket costs for patients living with MS. According to a
In addition to financial barriers, access to specialty treatments may also be limited by issues with coordination between pharmacists and practitioners. These barriers can often contribute to worse patient outcomes.
Shields Health Solutions, a subsidiary of Walgreens Boots Alliance, bills itelf is a specialty pharmacy accelerator dedicated to improving outcomes for people living with complex, chronic conditions, including MS.
In a recent
Shields reported an ARR of 0.18, which falls at the low end of the optimal range of 0.16 to 0.37. To achieve this benchmark, Shields says it collaborates with health systems throughout the U.S. to improve access to specialty pharmacies, assist with prior authorizations and identify financial assistance opportunities.
The company’s clinical team encompasses seven MS-certified specialists, including clinical pharmacists who review medical records to determine root causes for relapses, work with patients to improve medication adherence, and coordinate care with clinicians to manage patient relapses.
According to the Shields
Shields Health Solutions presented research posters and details on patient outcomes at this year’s
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.